IP Library Granted Patent US 9,233,956
Granted Patent B2
US 9,233,956 · App. 14/088,598 · Granted Jan 12, 2016

Benzene sulfonamide thiazole and oxazole compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,956
App. No.
14/088,598
Filed
Nov 25, 2013
Granted
Jan 12, 2016
Kind
B2
Art Unit
1624
USPC
435/6
Abstract

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Claims (11)

1. A method for treating a susceptible neoplasm selected from melanoma and non-small cell lung cancer in a mammal in need thereof comprising the steps of:

(a) analyzing a sample from said neoplasm to determine whether an activating mutation is present in the coding sequence for B-Raf in cells of said neoplasm;

(b) selecting a mammal having said neoplasm with an activating mutation in the coding sequence for B-Raf; and

(c) administering a therapeutically effective amount the compound of formula

or a pharmaceutically acceptable salt thereof to the mammal selected in step (b).

2. The method of claim 1 , wherein the activating mutation present in the coding sequence for BRAF results in a BRAF having an amino acid substitution selected from the group consisting of R462I, I463S, G464V, G464E, G466A, G466E, G466V, G469A, G469E, D594V, F595L, G596R, L597V, L597R, T599I, V600E, V600D, V600K, V600R, T119S, and K601E.

3. The method of claim 2 , wherein the activating mutation present in the coding sequence for BRAF results in a BRAF having a V600E amino acid substitution.

4. The method of claim 1 , wherein said neoplasm is melanoma.

5. The method of claim 4 , wherein said neoplasm is metastatic melanoma.

6. The method of claim 1 , wherein the activating mutation present in the coding sequence for BRAF results in the coding sequence of BRAF having a substitution of T1799A.

7. The method of claim 1 , wherein said mammal is a human.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2026
From: NOVARTIS AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 073557/0421 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 035812/0424 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: GLAXOSMITHKLINE LLC
To: GLAXO GROUP LIMITED
Reel/Frame 035806/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: GLAXO GROUP LIMITED
To: NOVARTIS PHARMA AG
Reel/Frame 035806/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2014
From: RHEAULT, TARA RENAE
To: GLAXOSMITHKLINE LLC
Reel/Frame 032301/0454 →